Glenmark Life Sciences Ltd
NSE:GLS
Glenmark Life Sciences Ltd
Cash from Financing Activities
Glenmark Life Sciences Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
G
|
Glenmark Life Sciences Ltd
NSE:GLS
|
Cash from Financing Activities
-₹3.9B
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Financing Activities
-₹12.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Financing Activities
-₹11.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Financing Activities
-₹54.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Cash from Financing Activities
-₹29.8B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Cash from Financing Activities
-₹7.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Glenmark Life Sciences Ltd's Cash from Financing Activities?
Cash from Financing Activities
-3.9B
INR
Based on the financial report for Mar 31, 2023, Glenmark Life Sciences Ltd's Cash from Financing Activities amounts to -3.9B INR.
What is Glenmark Life Sciences Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-42%
Over the last year, the Cash from Financing Activities growth was -392%. The average annual Cash from Financing Activities growth rates for Glenmark Life Sciences Ltd have been -42% over the past three years .